As a result, the state of Odisha has become the first in the country to buy the Tata MD CHECK OmiSure RT-PCR assays, which were developed in collaboration with the Indian Council of Medical Research (ICMR) and are designed particularly to detect the COVID-19 Omicron variant.
Tata Medical and Diagnostics Ltd. (Tata MD), the medical arm of the Tata Group, has received an order for 5 lakh tests from the Odisha State Medical Corporation Ltd (OSMCL), the firm announced on Monday. As a result, the state of Odisha has become the first in the country to buy the Tata MD CHECK OmiSure RT-PCR assays, which were developed in collaboration with the Indian Council of Medical Research (ICMR) and are designed particularly to detect the COVID-19 Omicron variant.
On Saturday, over 14 Omicron cases were discovered in Odisha, bringing the state’s total to 75. So far, one death has been reported in Odisha owing to Omicron. OSMCL, an independent procurement agency for the Government of Odisha’s Department of Health and Family Welfare, would acquire the kits. “The only test that can detect the Omicron variant at the time of testing is OmiSure.” Odisha is the first state in the country to choose TATA MD OmiSure for COVID testing, and the state will offer all required support, according to Girish Krishnamurthy, CEO and Managing Director of Tata Medical and Diagnostics.
The only test approved by the ICMR for RT-PCR detection of the Omicron variant is Tata MD’s OmiSure. It uses a unique design to identify simultaneous S-gene Target Failure (SGTF) and S-Gene Mutation Amplification using a single tube, fully multiplexed assay (SGMA). Its confirmatory examination of RdRP target with internal controls results in precise diagnosis with a significant reduction in the possibility of false-positive reactions due to contamination in control materials. OmiSure follows a conventional qPCR process that is compatible with most 4+ channel qPCR machines.
amfnews